NCT02690064View on ClinicalTrials.gov

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

NAActive, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Cystic Fibrosis
Interventions
DIETARY_SUPPLEMENT

Acute Antioxidant

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

DIETARY_SUPPLEMENT

Chronic Antioxidant

Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.

OTHER

Placebo

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Trial Locations (1)

30912

Georgia Prevention Institute, Augusta

All Listed Sponsors
lead

Augusta University

OTHER

NCT02690064 - Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF | Biotech Hunter | Biotech Hunter